KFSHRC First in the Middle East to Implant AI-Powered Brain-Sensing Device for Treating Neurological Disorders
RIYADH, Saudi Arabia, June 11, 2025 (GLOBE NEWSWIRE) -- In a landmark medical achievement, King Faisal Specialist Hospital & Research Centre (KFSHRC) has become the first institution in the Middle East to successfully implant an AI-powered brain-sensing device designed for the treatment of complex neurological disorders. The breakthrough ushers in a new era of real-time, adaptive neuromodulation therapy, offering renewed hope for patients suffering from Parkinson's disease, epilepsy, and other movement disorders.
The device utilizes artificial intelligence to continuously monitor the brain's electrical activity, identifying abnormal neural signals and delivering precisely targeted electrical impulses to restore neurological balance. Powered by a closed-loop system, the device automatically adjusts stimulation in real time based on the patient's brain activity, enabling highly responsive, personalized therapy and consistent symptom control throughout the day.
The minimally invasive procedure, typically completed within three to five hours, has shown the potential to reduce patients' reliance on medication by as much as 50%. This cuts down detrimental side effects and enhances patients' autonomy and quality of life. Initial outcomes suggest rapid post-operative recovery and tangible improvements in symptom control within weeks.
This breakthrough reflects the leadership and clinical excellence of KFSHRC's Neuroscience Centre of Excellence, which provides comprehensive, multidisciplinary care for adult and paediatric neurological cases. The Center leads the region in deep brain stimulation (DBS) for movement disorders, stereotactic EEG for epilepsy, and AI-based diagnostics for cognitive conditions and autism. Through continuous innovation and a patient-centred approach, it is redefining regional standards in neuroscience and setting new benchmarks in precision brain health.
It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally in the list of the world's top 250 Academic Medical Centres for the third consecutive year and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/21272d69-c84e-4163-abd2-48d6c9270806
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed with 67% (29/43) CR rate, 88% (38/43) ORR, and 100% (37/37) MRD negativity among responders – – Enrollment underway in pivotal Ph 3 EVOLVE-2 trial evaluating revumenib with ven/aza in newly diagnosed mNPM1 AML patients unfit for intensive chemotherapy – NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the BEAT AML trial of revumenib in combination with venetoclax and azacitidine (ven/aza) in newly diagnosed mutant NPM1 (mNPM1) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) patients were published in the Journal of Clinical Oncology and simultaneously presented in an oral session at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy and virtually. 'The data observed in BEAT AML underscore the potential for revumenib with ven/aza to improve outcomes for newly diagnosed mNPM1 or KMT2Ar AML patients who are not eligible for intensive chemotherapy, a population that continues to face poor long-term outcomes despite recent advances,' said Nick Botwood, M.B.B.S., Head of Research & Development and Chief Medical Officer at Syndax. 'These data, along with the results from other trials of revumenib in different settings, highlight revumenib's potential to become a cornerstone therapy for all menin-dependent acute leukemias across the treatment continuum.' 'These data support the ability to combine revumenib with ven/aza in the frontline setting and the clinical activity observed highlights the potential for the triplet to provide high rates of complete remission and MRD-negativity, two treatment goals associated with improved clinical outcomes,' said Joshua F. Zeidner, M.D., Chief, Leukemia Research at the University of North Carolina, Lineberger Comprehensive Cancer Center and Principal Investigator in the BEAT AML trial. 'Overall, the data we observed in BEAT AML are very encouraging and suggest that the ongoing EVOLVE-2 pivotal frontline trial evaluating the triplet in unfit mNPM1 AML patients could deliver practice-changing results.' Summary of Results from BEAT AML Phase 1 Trial The publication and EHA presentation report updated results from the Phase 1b BEAT AML trial evaluating the safety and clinical activity of revumenib in combination with venetoclax/azacitidine in newly diagnosed older adults (≥60 years) with mNPM1 or KMT2Ar AML. The trial is being conducted as part of The Leukemia & Lymphoma Society's Beat AML® Master Clinical Trial (NCT03013998). As of September 2024, 43 patients were enrolled and treated in BEAT AML across two dose levels of revumenib (113 mg q12 or 163 mg q12h with strong CYP3A4 inhibitor azoles) in combination with venetoclax and azacitidine. Overall, 79% (34/43) of patients had mNPM1 AML and 21% (9/43) had KMT2Ar AML. The median age was 70 years (range: 60-92) and 40% were ≥75 years. Revumenib was generally well tolerated at both dose levels in combination with venetoclax and azacitidine without a maximal tolerated dose identified. The most common overall non-hematologic treatment-emergent adverse events (TEAEs) of any grade were nausea (60%), constipation (53%), QTc prolongation (44%), hypokalemia (44%), and vomiting (42%). Overall Grade ≥3 non-hematologic AEs were rare and similar between both dose levels. In the intent-to-treat population, the observed rate of complete remission (CR) was 67% (29/43), composite complete remission (CRc) was 81% (35/43), and the overall response rate (ORR) was 88% (38/43). Among 37 patients with measurable residual disease (MRD) response assessment, 100% were MRD negative by centralized flow cytometry testing (sensitivity of 0.02%). The median duration of CRc was 12.0 months (95% CI: 7.8-not reached). 23% (10/43) of patients had proceeded to hematopoietic stem cell transplantation (HSCT) as of the February 2025 data cut off. In an early analysis of survival from this single-arm trial (median follow-up of 6.9 months), the median overall survival (OS) observed was 15.5 months (95% CI: 9.5-19.5). Subset analysis showed a CRc rate of 77% and an observed median OS of 15.5 months in mNPM1 patients with intermediate risk by ELN 2024 (n=17), and a CRc rate of 89% and observed median OS of 18.0 months in KMT2Ar patients (n=9). In contrast, historical data from newly diagnosed mNPM1 patients with intermediate risk treated with venetoclax and azacitidine show a CRc of 57% and median OS of 9.9 months.1 In newly diagnosed KMT2Ar AML patients treated with venetoclax and hypomethylating agent therapy, a CRc rate of 43% and median OS of 2.5 months was observed in a retrospective analysis.2 About Revuforj® (revumenib) Revuforj (revumenib) is an oral, first-in-class, selective menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. Revumenib is in development for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1). Positive pivotal data from the AUGMENT-101 trial in this population with revumenib as a monotherapy were recently published and the Company completed the submission of a supplemental NDA for revumenib in R/R mNPM1 AML in April 2025. Additionally, multiple trials of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2A-rearranged acute leukemia are ongoing or planned across the treatment landscape, including in newly diagnosed patients. Revumenib was previously granted Orphan Drug Designation for the treatment of AML, ALL and acute leukemias of ambiguous lineage (ALAL) by the U.S. FDA and for the treatment of AML by the European Commission. The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and Breakthrough Therapy Designation for the treatment of adult and pediatric patients with R/R acute leukemia harboring a KMT2A rearrangement. IMPORTANT SAFETY INFORMATION WARNING: DIFFERENTIATION SYNDROME Differentiation syndrome, which can be fatal, has occurred with Revuforj. Signs and symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and renal dysfunction. If differentiation syndrome is suspected, immediately initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution. WARNINGS AND PRECAUTIONS Differentiation syndrome: Revuforj can cause fatal or life-threatening differentiation syndrome (DS). Symptoms of DS, including those seen in patients treated with Revuforj, include fever, dyspnea, hypoxia, peripheral edema, pleuropericardial effusion, acute renal failure, and/or hypotension. In clinical trials, DS occurred in 39 (29%) of 135 patients treated with Revuforj. DS was Grade 3 or 4 in 13% of patients and fatal in one. The median time to onset was 10 days (range 3-41 days). Some patients experienced more than 1 DS event. Treatment interruption was required for 7% of patients, and treatment was withdrawn for 1%. Reduce the white blood cell count to less than 25 Gi/L prior to starting Revuforj. If DS is suspected, immediately initiate treatment with systemic corticosteroids (e.g., dexamethasone 10-mg IV every 12 hours in adults or dexamethasone 0.25-mg/kg/dose IV every 12 hours in pediatric patients weighing less than 40 kg) for a minimum of 3 days and until resolution of signs and symptoms. Institute supportive measures and hemodynamic monitoring until improvement. Interrupt Revuforj if severe signs and/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids, or earlier if life-threatening symptoms occur such as pulmonary symptoms requiring ventilator support. Restart steroids promptly if DS recurs after tapering corticosteroids. QTc interval prolongation: In the clinical trials, QTc interval prolongation was reported as an adverse reaction in 39 (29%) of 135 patients treated with Revuforj. QTc interval prolongation was Grade 3 in 12% of patients. The heart-rate corrected QT interval (using Fridericia's method) (QTcF) was greater than 500 msec in 8%, and the increase from baseline QTcF was greater than 60 msec in 18%. Revuforj dose reduction was required for 5% of patients due to QTc interval prolongation. QTc prolongation occurred in 16% of the 31 patients less than 17 years old, 33% of the 88 patients 17 years to less than 65 years old, and in 50% of the 16 patients 65 years or older. Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to treatment with Revuforj. Perform an electrocardiogram (ECG) prior to initiation of Revuforj, and do not initiate Revuforj in patients with QTcF >450 msec. Perform an ECG at least once weekly for the first 4 weeks and at least monthly thereafter. In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring may be necessary. Concomitant use with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation. Interrupt Revuforj if QTcF increases >480 msec and <500 msec, and restart Revuforj at the same dose twice daily after the QTcF interval returns to ≤480 msec Interrupt Revuforj if QTcF increases >500 msec or by >60 msec from baseline, and restart Revuforj twice daily at the lower-dose level after the QTcF interval returns to ≤480 msec Permanently discontinue Revuforj in patients with ventricular arrhythmias and in those who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia. Embryo-fetal toxicity: Revuforj can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Revuforj and for 4 months after the last dose of Revuforj. ADVERSE REACTIONS Fatal adverse reactions occurred in 4 (3%) patients who received Revuforj, including 2 with differentiation syndrome, 1 with hemorrhage, and 1 with sudden death. Serious adverse reactions were reported in 99 (73%) patients. The most frequent serious adverse reactions (≥5%) were infection (24%), febrile neutropenia (19%), bacterial infection (17%), differentiation syndrome (12%), hemorrhage (9%), and thrombosis (5%). The most common adverse reactions (≥20%) including laboratory abnormalities, were hemorrhage (53%), nausea (51%), phosphate increased (50%), musculoskeletal pain (42%), infection (41%), aspartate aminotransferase increased (37%), febrile neutropenia (35%), alanine aminotransferase increased (33%), parathyroid hormone intact increased (33%), bacterial infection (31%), diarrhea (30%), differentiation syndrome (29%), electrocardiogram QT prolonged (29%), phosphate decreased (25%), triglycerides increased (25%), potassium decreased (24%), decreased appetite (24%), constipation (23%), edema (23%), viral infection (23%), fatigue (22%), and alkaline phosphatase increased (21%). DRUG INTERACTIONS Drug interactions can occur when Revuforj is concomitantly used with: Strong CYP3A4 inhibitors: reduce Revuforj dose Strong or moderate CYP3A4 inducers: avoid concomitant use with Revuforj QTc-prolonging drugs: avoid concomitant use with Revuforj. If concomitant use is unavoidable, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold Revuforj if the QTc interval is >480 msec. Restart Revuforj after the QTc interval returns to ≤480 msec. SPECIFIC POPULATIONS Lactation: advise lactating women not to breastfeed during treatment with Revuforj and for 1 week after the last dose. Pregnancy and testing: Revuforj can cause fetal harm when administered to a pregnant woman. Verify pregnancy status in females of reproductive potential within 7 days prior to initiating Revuforj. Pediatric: monitor bone growth and development in pediatric patients. Geriatric: compared to younger patients, the incidences of QTc prolongation and edema were higher in patients 65 years and older. Infertility: based on findings in animals, Revuforj may impair fertility. The effects on fertility were reversible. To report SUSPECTED ADVERSE REACTIONS, contact Syndax Pharmaceuticals at 1-888-539-3REV or FDA at 1-800-FDA-1088 or Please see Full Prescribing Information, including BOXED WARNING. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on X and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, the acceptance of Syndax and its partners' products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj's or Niktimvo's commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. All other trademarks are the property of their respective owners. References Döhner H, et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood 2024; 144 (21): 2211– 222. Gangat N, et al. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. Am J Hematol. 2025;100(2):260-271. Syndax Contact Sharon KlahreSyndax Pharmaceuticals, Tel 781.684.9827 SNDX-G
Yahoo
21 minutes ago
- Yahoo
Plant Medicine Track at Psychedelic Science 2025 Spotlights Ancestral Wisdom, Indigenous Sovereignty, and Being in Right Relationship
• From Peyote conservation to Religious Freedom, the Plant Medicine Track honors ancestral traditions, uplifts Indigenous leadership, and promotes ethical and reciprocal relationships with the stewards of these sacred medicines. • Featuring voices from the Amazon, Wirikuta, Sierra Mazateca (Oaxaca), and tribal nations within the United States, speakers include Sandor Iron Rope, Osiris Garcia Cerqueda, Daiara Tukano, Christine McCleave, Chief Nixiwaka Yawanawá, and Raine Piyãko. • Sessions explore ancestral healing practices, biocultural conservation, Indigenous sovereignty, sacred plant protection, and the ethics of Psychedelic Science and policy reform. DENVER, June 12, 2025 (GLOBE NEWSWIRE) -- With growing recognition of psychedelics and plant medicines in therapeutic and scientific settings, it is a critical time to uplift and acknowledge the Indigenous wisdom and practices that preceded and guide today's progress. Psychedelic Science 2025 (PS2025) honors these roots with a dedicated Plant Medicine Track that highlights spiritual, cultural, and ecological dimensions of Indigenous practices with sacred plants. Hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), PS2025 takes place June 16–20 at the Colorado Convention Center in Denver. With more than 500 speakers across five days, the gathering convenes a global community of scientists, healers, advocates, leaders, and Indigenous knowledge-keepers. Among its many offerings, the Plant Medicine Track stands out as an immersive and robust forum covering ancestral traditions, religious freedom, Indigenous sovereignty, and biocultural healing practices, and their intersection with the psychedelic movement. The Plant Medicine Track weaves together a rich spectrum of themes, from preserving endangered sacred plants and habitats, to whether we can responsibly integrate Indigenous knowledge in contemporary therapy and science, to utilizing modern psychedelic therapy practices to support the healing of tribal, Native, and other Indigenous communities across the world. Key focus areas include: Biocultural Protection – Safeguarding sacred plants and their ecosystems (for example, the peyote cactus in Wirikuta and South Texas (the Chihuahuan Desert) alongside the cultures that revere them, blending conservation with cultural rights. Indigenous Leadership – Highlighting Indigenous voices and sovereignty in the psychedelic ecosystem, including thoughtful perspectives from elders and youth alike on how to respect, share, and regulate plant medicines in today's globalized world. Grassroots Healing – Spotlighting community-driven healing initiatives that merge ancestral practices with modern approaches to address challenges like addiction, trauma, and social inequality. Legal & Ethical Frameworks – Exploring the evolving legal landscape and ethical guidelines for sacred medicine use – from religious freedom and policy reform to protocols for respectful engagement and benefit-sharing with Indigenous communities. 'One of the most important themes of Psychedelic Science 2025 is the relationship between the psychedelic movement and the many Indigenous communities that preceded it, participate in it, and are impacted by it. MAPS is proud to work alongside, learn from, and be in relationship with tribal, Native American/Alaska Native, and Indigenous people from across the country and the world. We honor the spectrum of identity represented by land-based practices, celebrate efforts to reclaim or reconnect to them, and acknowledge the complexity that comes alongside navigating indigeneity and territoriality in a globalized world. The Plant Medicine Track is one way we highlight these topics and ensure that the contemporary psychedelic movement remains grounded in respect, reciprocity, and reverence for its roots.' — Ismali Lourido Ali, J.D., Interim Co-Executive Director, MAPS From legacy Indigenous healers and dedicated conservationists to activists and cutting-edge scientists, PS2025's Plant Medicine Track focuses on the deep connections between culture, ecology, and healing that drive the psychedelic field – and the responsibility we all have to our larger community. Thanks to US-based nonprofit organizations, including the Indigenous Medicine Conservation Fund (IMC Fund), which works to directly lift up voices from Indigenous communities around the world, and the Chacruna Institute, which maintains an incredible commitment to including Indigenous voices in the psychedelic ecosystem. It behooves all of us to educate ourselves on these delicate subjects, and MAPS is proud to be highlighting the vision and the possibility that this psychedelic effort can continue without doing harm. Indigenous-Led Sessions – Talks and panels on multiple stages that are guided by Indigenous elders and knowledge-keepers from across the Americas, Africa, and beyond, sharing perspectives rarely heard outside their communities. Cross-Cultural Exchange – Dialogues bridging traditional wisdom with modern science, and connecting different generations and cultures to foster mutual learning about healing, conservation, and community well-being. Ethical & Sustainable Practices – Forward-looking discussions on tensions that come with integrating psychedelics into society, including the establishment of entheogenic churches, international policy on Indigenous rights, and best practices for reciprocity, sustainability, and ecological responsibility. Alliance-Building – Networking opportunities to connect with Indigenous leaders, researchers, and fellow advocates, and opportunities to forge partnerships and alliances to support biocultural conservation and cross-cultural initiatives around the world. Featured Sessions Setting the Principles for Cultural Appreciation and Respectful RelationshipTo kick off the Plant Medicine Track, this panel features an international delegation of Indigenous medicine practitioners, Raine Piyåko (Vice President, Yorenka Tasorentsi Institute), Steven Benally (Founding Board Member, Indigenous Peyote Conservation Initiative), Georges Gassita (Secretary General of the Board of Directors, Blessings of the Forest Gabon), and Madsa' Juårez (as moderator; Co-Executive Director, Indigenous Medicine Conservation Fund) will explore respectful interaction with medicines and the people that steward them, opening the track for the possibility of Cultural Appreciation and proper knowledge sharing. Sacred or Stolen? The Fine Line Between Cultural Appreciation and Appropriation in Psychedelic Healing As plant medicine gains mainstream attention, there's growing concern over who controls the narrative and who benefits. Are Western psychedelic practitioners honoring Indigenous traditions or erasing them? This conversation with Lígia Duque Platero, Ph.D. (Education Program Associate, Chacruna Institute), Osiris García Cerqueda, Ph.D. (Indigenous Mazatec historian and sociologist), and Nico Gusac (as moderator) explores cultural appropriation, reciprocity, and ethical ways to engage with plant medicine traditions without perpetuating harm. Declaration from the Indigenous Medicine Conservation Fund to Psychedelic ScienceOn the Keynote stage, Christine McCleave (CEO, National Native American Boarding School Healing Coalition) and Daiara Tukano, MA (Indigenous Rights Activist, Brazil) will read the Declaration from the IMC Fund Indigenous Delegation to PS2023 which was published after the previous conference, with new additions based on two days of discussion in the plant medicine track at PS2025. Peyote: History, Biocultural Considerations and Indigenous PerspectivesIt was only as recently as 1994 that the right of Native American Church members to practice with their sacred Peyote medicine was guaranteed by the Native American Freedom of Religion Act. Today, wild Peyote cactus populations are extremely at risk. This panel brings together Sandor Iron Rope (Board Member, Indigenous Peyote Conservation Initiative) and Lucy Benally (Board Member, Indigenous Medicine Conservation Fund), members of the Native American Church, to discuss advances and possibilities for the future of the Peyote cactus and the people who utilize it as their way of life. Moderated by Miriam Volat, MA (Co-Director, Riverstyx Foundation). Ayahuasca: Biocultural Overview and Indigenous ConsiderationsThe globalization of ayahuasca over the past several decades has had multifaceted impacts on Indigenous communities across the Amazon basin. This panel brings together Indigenous leaders from Peru, Colombia, and Brazil who are actively working for the conservation of their cultural heritages and toward the proper use of ayahuasca as a medicine. Miguel Evanjuanoy Chindoy (Co-Director, Indigenous Medicine Conservation Fund), Chief Nixiwaká Biraci Yawanawá (Spiritual and political leader, Yawanawá people, Brazilian Amazon), Chief Yama Nomanawa (Leader, Noke Koi villages, Brazil), and Daiara Tukano, MA (as moderator) will discuss pertinent themes from on-the-ground experiences at the intersection of preserved traditional practices and the Western market, including collective efforts like forming an ancestral doctor's union, leveraging Western interest in ayahuasca to benefit Indigenous communities, and advancing territorial rights in the face of foreign industrial interests. Churches and the New Psychedelic Emergence: Ancestral Medicines and the Growing MovementThe Religious Freedom Restoration Act provides a legal mechanism for church groups in the United States to use otherwise-scheduled medicines and substances as part of their so-called religious practices. But what are Indigenous perspectives on this movement? Walter López (President, ASOMASHK), Sandor Iron Rope (Board Member, Indigenous Peyote Conservation Initiative), Sean McAlliser (Attorney), and Miriam Volat, MA (as moderator) will describe the international frameworks that exist for the protection of Indigenous knowledge and resources, examine concerns around the legalization of psychedelic churches from the viewpoint of Indigenous leaders, and offer considerations for the way forward. Romantic Delusions: What We're Not Talking About in Plant Medicine Circles?Cassandra Muileboom will moderate a discussion between Bia Labate, Ph.D. and Nico Gusac of the Chacruna Institute that confronts the seductive narratives surrounding plant medicines—the romanticism, mystification, and spiritual consumerism that often obscure uncomfortable truths. It critically examines how plant medicine culture frequently glosses over issues of risk, trauma, mental health crises, and abuse. The conversation also explores how the idolization of 'healers,' particularly within Indigenous and neo-shamanic contexts, fosters environments ripe for power abuse and spiritual bypassing. It further tackles the problematic idealization of Indigenous peoples as pure, enlightened stewards of the Earth—an image that erases complexity, material struggle, and political demands. International Legal Frameworks, Indigenous Medicine, and the Psychedelic MovementDaiara Tukano, MA, Patricia Tóbon Yagarí (Indigenous lawyer, Colombia), Christine McCleave and Madsa' Juárez (as moderator) map out the landscape of global policies that intersect with Indigenous medicine traditions. From United Nations agreements on biodiversity and traditional knowledge to evolving drug laws in countries like the United States, Mexico, and Gabon, this session highlights how well (or poorly) current frameworks safeguard Indigenous communities and their sacred plants. It also challenges psychedelic advocates to go beyond legal minimums by adopting higher standards of respect, benefit-sharing, and ecological responsibility, sharing real examples of both progress and ongoing challenges at this critical intersection. Indigenous-Led Biocultural Conservation Success Stories with Ayahuasca, Iboga, and PeyoteActivism for policy change can be a hugely unifying force. MAPS Interim Co-Executive Director Ismail Lourido Ali will moderate a Keynote stage panel of high-profile lawyers, Patricia Tobón, Georges Gassita, and James Botsford, all of who have worked in Indigenous movements for decades, to discuss how protections for Indigenous rights — specifically related to Indigenous sacred medicine use — directly benefits communities and conservation efforts on the ground. Chacruna Sidebar Conversations: Sacred Plants, Decolonial DialoguesThe Chacruna Institute is offering dedicated conversations within the hallway of the convention center, with the intention to foster deep connection, collective wisdom, and community empowerment within the psychedelic field. These gatherings will include conversations such as 'From Reciprocity to Sovereignty: Sacred Plants Conservation and Community,' with Osiris García Cerqueda, Ph.D., Lígia Duque Platero, Ph.D., Karina Alvarez, and Marta Camagna; 'Healing with Plants: An Intimate Conversation with Maestro José López and Anne-Laure Vincke; and more. Other featured voices in the Plant Medicine Track include Stanley Krippner, Ph.D. (pioneering psychologist and shamanism researcher), David Bronner (Cosmic Engagement Officer, Dr. Bronner's), and many more – each adding a unique perspective from traditional knowledge to modern science. Together, these speakers embody the inclusive spirit of Psychedelic Science 2025, where ancient wisdom and contemporary research unite to shape the future of healing. Visit to view the full schedule, register for workshops, and explore hotel and travel options. Workshop spaces are limited and available on a first-come basis. About Psychedelic SciencePsychedelic Science 2025 (PS2025), hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), is the world's leading psychedelic conference. Returning to the Colorado Convention Center in Denver from June 16-20, 2025, this five-day event brings together a global community of scientists, therapists, policymakers, cultural leaders, and advocates to explore the forefront of psychedelic research, therapy, and culture. Facilitated by Superfly, known for producing iconic events such as Bonnaroo and Outside Lands, PS2025 will feature expert speakers; hands-on workshops; community events with art, music, and mindfulness activities; and scholarship opportunities to support broad participation. Since its inception in 2010, the Psychedelic Science conference series has fostered knowledge-sharing, collaboration, and community-building within the psychedelic ecosystem. Join thousands of attendees as we explore the transformative potential of psychedelics and shape the future of mental health, policy, and cultural understanding. For more information and registration details, visit and follow us on X, Instagram, LinkedIn, and Facebook. ABOUT MAPSFounded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS' conference flagship, Psychedelic Science, has been the leading convening of the psychedelic community since 2010. MAPS incubated Lykos Therapeutics, a drug-development public benefit company, and the Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $150 million to advance research, change drug policy, and evolve education in the field of psychedelics. CONTACTmedia@
Yahoo
26 minutes ago
- Yahoo
Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment
Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigator Second site, Regional Medical Oncology Center, also activated Recent Phase 1b clinical study results concluded continuous low dose lenalidomide provides meaningful efficacy and improved tolerability with no grade >3 drug-related hematologic toxicity PARAMUS, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. ('Starton'), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today Gabrail Cancer Center (GCC) in Canton, Ohio is now activated and open for enrolling patients in its Phase 2a clinical trial evaluating their continuous low-dose lenalidomide, STAR-LLD, for the treatment of multiple myeloma (MM). Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study's lead investigator. Regional Medical Oncology Center, located in Wilson, NC, has also opened as the trial's second active clinical site. 'We are excited to announce this major milestone in our mission to bring breakthrough therapies to patients. This marks the next phase of development for our lead candidate, STAR-LLD, and represents a significant step forward for the entire team," stated Pedro Lichtinger, Chairman and Chief Executive Officer of Starton Therapeutics. 'We expect this study to expand on what we observed in our prior Phase 1b study, that continuous low-dose lenalidomide provides meaningful efficacy and improved tolerability,' added Dr. Jamie Oliver, Starton's Chief Medical Officer. 'The expanded cohort and dose escalation will help us determine the most effective dose, with the goal of maintaining acceptable safety and tolerability.' Starton, which recently presented the results of the Phase 1b portion of the study at the 2025 American Association for Cancer Research, will assess the safety and tolerability of low-dose lenalidomide in heavily treated MM patients. Continuous SC infusion (STAR-LLD) in combination with dexamethasone and a protease inhibitor (PI) will be compared to oral lenalidomide (Revlimid®) in combination with dexamethasone and a PI. The study will include at least 24 patients randomized to STAR-LLD and oral lenalidomide (Revlimid®). Up to 45 additional patients may be enrolled to identify the optimal dose for a future registrational study (based on ORR vs dose vs Grade 3-4 toxicity). Starton anticipates opening approximately 10 clinical sites. About STAR-LLD STAR-LLD is a continuous delivery lenalidomide (LLD) in development to expand and replace the standard-of-care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). A preclinical proof-of-concept study for subcutaneous STAR-LLD demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with daily lenalidomide, and shrank by 80% with STAR-LLD over a single 28-day cycle. The study also showed a 100% overall response rate (ORR) using continuous delivery LLD and 20% of animals in this cohort were tumor-free after 100 days, compared to a 0% ORR in animals treated with a 70% higher dose of lenalidomide given in single daily doses. In addition, a Phase 1b clinical study of six relapsed/refractory MM patients resulted in all patients that received STAR-LLD achieving an objective response (1 CR and 5 PRs); no patients experienced drug-related anemia, neutropenia, leukopenia, or thrombocytopenia greater than grade 2 in up to 12 cycles of therapy. The study concluded that continuous delivery of low dose lenalidomide (STAR-LLD) provides meaningful efficacy and improved tolerability with no grade > 2 drug-related hematologic toxicity. About Starton Therapeutics Starton Therapeutics is a clinical-stage biotechnology platform company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer live better, for longer. Starton's proprietary technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. To learn more, visit Forward Looking Statements All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding our plans and objectives for future operations and expectations about current and future clinical trials, constitute 'forward-looking statements.' Forward-looking statements are subject to numerous conditions and known and unknown risks and uncertainties that could cause our actual results or events to differ materially from those included within the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, and except as required by law, Starton undertakes no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise. Investor Relations Contact Alex StarrManaging Director LifeSci Advisors astarr@ in to access your portfolio
